|
|
||||||||

,§
,§
*
University of Pittsburgh Cancer Institute, and Departments of
Medicine,
Surgery, and
§
Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA 15213
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
, and lymphotoxin. The second
type of Th cells, Th2, generally mediates humoral immunity and also
displays a unique cytokine secretion profile, including IL-4, IL-5, and
IL-10 1, 2 . Several of these cytokines, along with certain
APC-derived cytokines such as IL-1 and IL-12, are involved in
complex differentiation and cross-regulation pathways between Th1 and
Th2 cells. These pathways of differentiation and cross-regulation
between Th1/Th2, which have both been recently reviewed 3, 4, 5, 6, 7, 8 , have
positive or stimulatory, and negative or inhibitory components.
Two of the cytokines involved in Th1/Th2 interactions, IL-4 and IL-12,
have been shown to be essential for differentiation of Ag-activated
precursor T cells, termed Th0, into the two Th subtypes. IL-12 acts
with IFN-
to strongly promote differentiation into Th1, and IL-4
acts similarly for the generation of Th2 3, 5, 7 . Thus, with regard
to these differentiation-promoting functions, IL-4 and IL-12 are
mutually antagonistic. In fact, when Th0 cells differentiate into Th2
in the presence of IL-4, their ability to respond to IL-12 is rapidly
extinguished (within 1648 h) 9, 10 . This has been shown to be due
to down-regulation of the signaling chain (the ß2-chain) of the
heterodimeric IL-12R 11, 12 .
Following differentiation, Th1 cells have been shown to be able to
respond to both IL-4 and IL-12. IL-4 acts as a direct stimulus to
promote proliferation in Th1 cells that have been activated by Ag
stimulation through the TCR 13 . Th1 cells typically do not respond to
IL-4 in the absence of TCR ligation. Furthermore, IL-4 can synergize
with the autocrine Th1 growth factor IL-2 to induce high levels of
proliferation 13, 14, 15 . IL-12, on the other hand, has no ability to
directly stimulate Th1 proliferation, but rather acts as a
costimulatory molecule, allowing enhanced Th1 responsiveness to
cytokines produced after TCR ligation 16 . IL-12 also is a potent
inducer of IFN-
production by Th1 17 .
The effects of IL-4 and IL-12 on Th cell differentiation are
essentially mutually exclusive. However, there are examples in which
IL-4 and IL-12 interact simultaneously in the same cell, and this can
occur in various types of cells. In macrophages and dendritic cells,
IL-12 production was inhibited by IL-4 when the cells were stimulated
with LPS and IFN-
, whereas IL-12 production induced by CD40-CD40
ligand interaction was enhanced by IL-4 18 . IL-12 enhances
differentiation of murine erythroid progenitor cells induced by
erythropoietin plus IL-4 19 . The two cytokines have also been
described to interact in T cells. They have been shown to
synergistically promote CTL responses 20 . An IL-4-dependent cell line
CT4S responds to IL-4 and IL-12 in a synergistic fashion 21 , and
Kennedy et al. demonstrated that murine Th1 clones responded to a
combination of IL-4 and IL-12 16 . Interestingly, their Th1 cells did
not have to be activated by stimulation through the TCR to be able to
respond to the two cytokines.
The observation by Kennedy et al. 16 that IL-4 plus IL-12 induced proliferation in resting Th1 in an Ag-independent manner prompted us to investigate the mechanism by which proliferation is stimulated, and also to determine whether this in vitro phenomenon could represent a novel Th1/Th2 cross-regulatory pathway. We hypothesized that Th2 cells could positively regulate resting Th1 cells through the direct action of IL-4 and the indirect action of IL-12 derived from APC. We present in this work the results of our attempts to better understand the action of IL-4 plus IL-12 on Th1, and to assign biological significance to the phenomenon.
| Materials and Methods |
|---|
|
|
|---|
Female DBA/2J mice used for these studies were purchased from The Jackson Laboratory (Bar Harbor, ME). They were used between 2 and 6 mo of age.
Cells and lines
Th lines and clones were generated as previously described 22 .
Briefly, female DBA/2J mice were immunized at the base of the tail with
100 µg of synthetic peptide in CFA. The two peptides used were
derived from sperm whale myoglobin (SpW Mb) protein (amino acids
110121 and 132147) and were synthesized by the University of
Pittsburgh Peptide Synthesis Facility (Pittsburgh, PA). Clones were
generated from inguinal lymph node cell lines by standard techniques.
Clones and lines were maintained in RPMI 1640 (Life Technologies, Grand
Island, NY) supplemented with HEPES (10 mM), penicillin (100
U/ml), streptomycin (10 µg/ml), 2-ME (0.16 mM),
L-glutamine (2 mM), and 10% FCS (Life Technologies), and
were restimulated every 1014 days with irradiated (2500 rad)
syngeneic spleen APCs and specific antigenic peptide. Cytokine
expression was used to delineate Th1 (expressing IL-2 and IFN-
) and
Th2 (expressing IL-4 or IL-10) phenotypes. The lines AII (110121
specific) and 132 (132147 specific) were polarized for the production
of Th1 and Th2 cytokines, respectively. Clones A.2.5S and A.4.3 (both
110121 specific) were shown to be Th1, and clone 31.F.6 was shown to
be Th2. The Th2 clone 13.26 has been described previously 23 .
Spleen T cells were purified by a multistep depletion process. Culture medium used for T cell preparation was DMEM (Life Technologies) supplemented as described above. Fresh spleen cells were first incubated in plastic cell culture plates (#3003 plates; Falcon) for 4560 min at 37°C, with 5 x 107 cells in 5 ml medium per plate. After gentle rinsing, nonadherent cells were incubated with anti-B cell mAb-containing hybridoma culture supernatant (anti-B220) and anti-MHC class II mAb supernatant (MKD6; anti-I-Ad) for 30 min at 4°C. This was followed by incubation with rabbit complement (diluted 1/10 in culture medium, Cedarlane Low-Tox-M rabbit complement; Accurate Chemical, Westbury, NY) for 40 min at 37°C. Cells prepared in this fashion generally were greater than 95% T cells, as determined by staining for specific T cell markers and flow cytometry, as described previously 22 .
Spleen-derived APCs were prepared by complement depletion, as described above, using anti-Thy-1.2 24 mAb-containing hybridoma culture supernatant to remove T cells. APCs were irradiated with 2500 rad before use.
Proliferation assays
T cells were plated in 96-well microtiter culture plates (Corning Glass, Corning, NY) with 5 x 104 cells/well. Cytokines and or anti-cytokine mAbs were added, and the total culture volume was adjusted to 0.2 ml. Experiments using Th clones were performed using RPMI-based culture medium, and those using splenic T cells with DMEM-based culture medium. Cultures were incubated at 37°C for 24 h, at which time the wells were pulsed with [3H]thymidine ([3H]TdR; DuPont NEN, Boston, MA) at 0.5 µCi/well. [3H]TdR incorporation was measured by harvesting cells onto filter plates using a 96-well cell harvester (Packard Instrument, Downers Grove, IL) and counting on a TopCount liquid scintillation counter (Packard).
Cytokines used in these assays included IL-1 (Genzyme, Cambridge, MA), IL-2 and IL-4 (R&D Systems, Minneapolis, MN), and IL-12 (3.5 x 105 U/per µg; a gift from Dr. M. Lotze, University of Pittsburgh, PA). These cytokines were neutralized by mAbs including anti-IL-2 (PharMingen, San Diego, CA), anti-IL-4 25 (10% hybridoma 11B11 supernatant), and anti-IL-12 (G28-A; a gift from Dr. J. Flynn, University of Pittsburgh, PA). IL-1 was neutralized using IL-1R antagonist (R&D Systems). Assays of IL-1 and IL-4 responsiveness in Th2 were performed on plates that had been coated overnight with 10 µg/ml anti-TCR mAb (H57-597) 22, 26 .
Treatment of splenic T cells for generation of activated Th1 and Th2 effector cells
Activated Th effector cells were generated essentially as
previously described 27 . Fresh splenic T cells were cultured in
12-well plates (5 x 106 cells/well), with irradiated
T-depleted splenic APCs (1 x 107 cells/well), Con A
(2.5 µg/ml), and IL-2 (10 U/ml). Cells that had undergone such
treatment were referred to as having been generated under neutral
conditions. In addition, Th1 effector cells were generated by
adding IL-12 (50 U/ml) and anti-IL-4 (10% hybridoma 11B11
supernatant) to the reagents used to generate cells under neutral
conditions. Th2 effector cells were similarly generated using IL-4 (300
pM) and anti-IFN-
(10 µg/ml; PharMingen). Cells were
incubated under these three conditions for various lengths of time,
after which they were washed and purified on Ficoll-Hypaque (Sigma, St.
Louis, MO) before further use. The development of Th1 and Th2 effectors
was monitored by assaying culture supernatants for the Th1-specific
cytokine IFN-
, and the Th2-specific cytokine IL-5 by ELISA assay.
ELISAs were performed using cytokine-specific paired primary and
secondary reagents (PharMingen), as described 28, 29 .
Transwell assays
Assays of Th1/Th2 cytokine cross-regulation were performed using a dual chamber transwell culture system (Costar). Th2 clones or Con A-generated Th2 effector cells were placed in the bottom chamber of the transwell either alone, or following coating of the chamber with anti-TCR mAb. Variable numbers of Th2 cells were used depending on the particular experiment. Th1 clones or effectors (5 x 105 cells/well) were cultured in the upper chamber. Cells were incubated in this manner either alone or in the presence of IL-4, IL-12, or anti-IL-4 mAb. Total culture volume was 1 ml, which allowed for an approximate volume of 0.25 ml in the upper chamber. Assays with cytokine- or anti-TCR-stimulated cells were incubated for 24 or 48 h, respectively, before an 18-h pulse with [3H]TdR (2.5 µCi/well). Cells were transferred from the transwells into 96-well plates before harvesting and counting, as described above.
| Results |
|---|
|
|
|---|
Upon antigenic stimulation through the TCR, Th cells acquire the
ability to proliferate in response to cytokines. Typically, activated
Th cells respond to stimulation by cytokines for only a limited period
of time, after which they become refractory to further stimulation
15 . This principle is demonstrated in Fig. 1
for the response of a Th1 and a Th2
clone to IL-4 in the days following stimulation with specific Ag
presented by APC. Our clones, of which those in Fig. 1
are
representative, respond to IL-4 maximally at 2 days poststimulation. On
subsequent days, the response to IL-4 diminishes, until at some point
stimulation is entirely absent. The representative Th1 clone lost all
IL-4 responsiveness by 4 days poststimulation (Fig. 1
A),
whereas the Th2 clone retained some ability to proliferate in response
to IL-4, albeit at a greatly reduced level, 2 wk poststimulation (Fig. 1
B). Normally, our clones do not exhibit IL-4 responsiveness
beyond 57 days poststimulation, and are termed resting Th cells.
|
|
We attempted to define the mechanism by which IL-12 renders Th1
cells susceptible to stimulation by IL-4. First, we wanted to determine
whether the two cytokines had to be present together to induce Th1
proliferation, or if cells could be treated with IL-12 and then respond
to IL-4 subsequently in a manner analogous to antigenic stimulation
through the TCR, such as in Fig. 1
. Our previous work showed that in
some Th2 clones, IL-1 pretreatment mediates a subsequent, prolonged
responsiveness to IL-4 22 . In contrast, we and others found that
pretreatment with IL-12 for up to 24 h did not render Th1 cells
able to subsequently respond to IL-4 (16 and data not shown). In
fact, both IL-4 and IL-12 had to be present essentially throughout the
duration of a proliferation assay to stimulate a proliferative
response. A Th1 clone was incubated with IL-4 and IL-12, and
neutralizing Abs to either IL-4 or IL-12 were added at various times
poststimulation. When neutralizing mAbs to either IL-4 or IL-12 were
added at time points before 24 h after the beginning of the assay,
little or no proliferation was observed (Fig. 3
, A and B). Adding
either mAb beyond 24 h had no effect during the remaining 18
h of the assay (i.e., during the [3H]TdR pulse). These
results are in contrast to our results from experiments examining the
costimulatory effects of IL-1 on Th2 cells. In these experiments, the
presence of IL-1 was only required early, and maximal IL-4
responsiveness was observed after IL-1 had been present for 8 h
(Fig. 3
C). Similar to Th1, IL-4 had to be present throughout
the duration of the assay in order for IL-1 to elicit a response in Th2
(Fig. 3
D). In addition, the costimulatory effect of IL-1
required prior antigenic stimulation in the form of anti-TCR mAb
coated on the plate, which was not required in the case of IL-12
costimulating the IL-4 response in Th1.
|
We also tested whether IL-4 + IL-12 treatment of Th1 induced the
production of IL-2, which Th1 cells normally utilize for proliferation
following antigenic stimulation. However, proliferation of clone
A.2.5S, which responds to IL-2 constitutively (unpublished
observation), was unaffected by neutralizing Ab to IL-2 after treatment
with IL-4 + IL-12 (Fig. 4
B).
The amount of anti-IL-2 mAb used was able to inhibit comparable
levels of proliferation in the same clone in response to exogenously
added murine IL-2 (Fig. 4
A). Furthermore, RT-PCR analysis
showed no detectable IL-2 mRNA in cells stimulated with IL-4 + IL-12
(data not shown). Therefore, it appears that IL-12 and IL-4 could
interact within cells to promote proliferation, possibly through
common intracellular signaling pathways.
|
We have shown that IL-4 and IL-12, when present together, provide
a modest stimulatory signal to Th1 cells, and we know that the effect
occurs at low levels of IL-12 (as low as 0.1 U/ml, or 0.286 pg/ml, in
Fig. 2
). We wanted to determine whether IL-12 would allow Th1 to
proliferate in response to IL-4 at levels produced by Th2. To do this,
cultures were set up in transwell culture plates, which consists of
upper and lower chambers separated by a membrane filter that is
permeable to soluble factors such as cytokines, but not to cells. The
Th1 clone was cultured in the upper chamber, with a Th2 clone in the
lower chamber. A Th1 clone placed in the upper chamber proliferated in
response to IL-4 plus IL-12, and the response could be blocked by
neutralizing anti-IL-4 Ab (Fig. 5
A). Stimulation of the Th2
clone with anti-TCR mAb, which induced IL-4 production but not
proliferation (data not shown), had no effect on the Th1 unless IL-12
was added (Fig. 5
B). At the concentration of IL-12 used in
this experiment (50 U/ml or 143 pg/ml), there was some proliferative
response of the Th1 to IL-12 alone in some, but not all experiments. We
assume this IL-12-induced proliferation is the result of a failure of
the Th1 cells to reach a fully resting state in these cases, since
previously activated cells do appear to be able to respond to IL-12
alone for a period of time (for example, see Fig. 6
). However, stimulation of the Th2
clearly enhanced Th1 proliferation in the presence of IL-12, which
could be blocked by anti-IL-4 mAb (Fig. 5
B). The
anti-TCR mAb, which was coated onto the bottom of the lower
chamber, had no effect on the Th1 in the upper chamber in the absence
of Th2 or IL-12 (compare the second bars from the
left in Fig. 5
, A and B, which differ
only by the presence or absence of anti-TCR mAb). These results
suggest that this form of cross-regulation could occur in a natural
setting in which a Th2 effector response is underway in the
simultaneous presence of an IL-12 source, such as macrophages or
dendritic cells 33, 34, 35, 36 .
|
|
Effect of IL-4 + IL-12 can be observed in freshly derived T cell effectors
We assessed responses of normal T cells to IL-4 and IL-12. T cells
were purified from murine spleen and were assayed for responsiveness to
IL-4 and IL-12. Unlike the Th1 lines and clones (Fig. 2
), freshly
isolated spleen T cells exhibited no proliferation in response to IL-4
and IL-12 (Fig. 6
A). However, upon activation with Con A and
IL-2, a response was seen in response to both cytokines. Two days after
Con A stimulation, there was a vigorous response to either IL-4 or
IL-12 alone, and IL-12 slightly enhanced the IL-4 response,
particularly at lower concentrations of IL-4 (Fig. 6
B). By 6
days poststimulation, the response to IL-12 alone was absent, the
response to IL-4 alone was minimal, and IL-12 had a more significant
enhancing effect on the IL-4 response (Fig. 6
C).
We then treated spleen T cells with Con A + IL-2 alone and under
conditions that favor the development of Th1 or Th2 effector cells (Con
A + IL-2 and IL-12 + anti-IL-4, or IL-4 + anti-IFN-
,
respectively) 27 . Appropriate cytokines were generated under each of
the conditions (IFN-
for Th1 and IL-5 for Th2), as determined by
ELISA assay of culture supernatants (Fig. 7
, top panels). At 6 days
poststimulation, IL-12 slightly enhanced the IL-4 response in cells
stimulated under neutral conditions, as shown previously in Fig. 6
C (Fig. 7
A), and cells generated under
Th2-promoting conditions exhibited little or no IL-12 responsiveness
(Fig. 7
C). In cells generated under Th1-promoting
conditions, IL-12 induced a significant enhancement of proliferation
even at very low levels of IL-4 (Fig. 7
B). Therefore, normal
Th effector cells with a Th1 phenotype do respond to the combination of
IL-4 and IL-12 in an Ag-independent fashion in a manner analogous to
that previously observed in Th1 clones.
|
|
| Discussion |
|---|
|
|
|---|
, mediates the generation of
the Th1 subtype, and IL-4 promotes differentiation of Th0 to the Th2
subtype 3, 5, 7 . Therefore, it is generally thought that the roles of
IL-4 and IL-12 are mutually antagonistic. However, it has been shown
that Th1 clones that have returned to a resting, nonproliferating state
following antigenic stimulation could be induced to proliferate in an
Ag-independent manner by a combination of IL-4 and IL-12 16 . We have
confirmed these observations using our independently derived Th1 lines
and clones from a different strain of mice, suggesting that this may be
a general phenomenon. Furthermore, and most interestingly, we found
that IL-12 greatly enhanced the IL-4 response of activated normal
splenic Th1 cells, and that the combined effect of the two cytokines
became more prominent with time after activation, when the IL-4
response was waning. We hypothesized that the effect of IL-4 + IL-12
could represent a novel Th1/Th2 cross-regulatory pathway that benefits
Th1.
The combined effect of IL-4 and IL-12 may be a novel means of
maintaining a Th1 effector response that is waning due to, for example,
suboptimal concentrations of Ag. This could represent a way of
expanding the pool of Th1 effector cells, to generate a larger number
of cells capable of subsequently responding to specific Ag. Several
pieces of evidence support this hypothesis. The first is that IL-4 +
IL-12 clearly induces proliferation in Th1 clones and in Th1 effector
cells derived from normal spleen. The effect is observed at low (pg
range) levels of IL-12. In the presence of IL-12, Th1 effector cells
generated from normal spleen by Con A stimulation were particularly
responsive to low concentrations of IL-4 (Figs. 7
B and
8C). In addition, we showed that the amount of IL-4 produced
by in vitro stimulated Th2 effector cells was sufficient to promote
this effect (Fig. 8
). Con A-activated cells never completely lost their
ability to respond to IL-4 in the manner the Ag-stimulated Th1 clones
did, but the level of proliferation in response to IL-4 alone was
minimal by 6 days poststimulation at all but very high concentrations
of IL-4. As expected, since Th2 cells lack functional IL-12R, Th2
clones, as well as newly generated Th2 effector cells, were completely
unable to respond to IL-4 and IL-12, demonstrating that this is a
purely Th1 phenomenon. A similar unresponsiveness to IL-12 has been
observed in human T cells activated with PHA under conditions that
would result in the generation of Th2 37 . Therefore, all of our
evidence suggests that previously activated Th1 cells in vivo could
gain a survival advantage from a bystander effect mediated by
Th2-derived IL-4 and APC-derived IL-12.
IL-12 is a known costimulatory molecule for Th1 16 . The proliferative
effect of IL-4 + IL-12 on Th1 is similar to that seen in Th2 stimulated
by a combination of IL-1 and IL-4. IL-1 is able to prolong the response
of previously activated Th2 to IL-4 beyond the normally short period
(23 days) of poststimulatory IL-4 responsiveness 15 . A distinct
difference between the two effects is that while pretreatment of Th2
cells with IL-1 renders them able to respond to IL-4 for some time
afterward, IL-12 had to be present together with IL-4 to stimulate Th1
proliferation (Fig. 3
). It was not possible to pretreat Th1 cells with
IL-12 such that they would subsequently respond to IL-4 (data not
shown). The effects of IL-1 on Th2 and IL-12 on Th1 also differ in that
IL-1 is not a differentiation factor for Th2 like IL-12 is for Th1 5, 7 . Another possible costimulator of the IL-4 response in Th1 may be
IL-18, which is more like IL-1 in that it has similar functions as
IL-12, but does not appear to be a Th1 differentiation factor 38, 39 .
Cooperativity between IL-18 and IL-4 would likely occur via a pathway
distinct from IL-4 and IL-12 since IL-18 can induce IL-2 production
from Th1 38 , which would act with the IL-4 to synergistically promote
Th1 proliferation 13, 14, 15 . In contrast, we found no evidence that IL-2
was involved in Th1 proliferation in response to IL-4 + IL-12 (Fig. 4
).
A common thread between the autocrine IL-4 effect on Th2 involving
IL-1, and the cross-regulatory IL-4 effect on Th1 involving IL-12 is
that both cytokines can be produced by the same cell type, activated
macrophages 33, 34, 36 . So, although the B cell is the preferential
APC for Th2 8 , these similar pathways are likely to occur, at
least to varying degrees, in the same environment.
As mentioned above, proliferation of Th1 in response to IL-4 + IL-12
did not appear to involve IL-2 production. Further attempts were made
to define the mechanism by which IL-12 appears to promote IL-4
responsiveness in Th1. Since IL-4 does not appear to alter IL-12R
expression 37 , and because IL-12 is known to act on Th1 only as a
costimulator, and not as a direct inducer of proliferation, we examined
IL-4R expression. However, expression of the IL-4R did not appear to be
altered either at the cell surface protein or mRNA levels. The only
plausible remaining explanation is that modulation of intracellular
signaling pathways may be involved. IL-12 and IL-4 both signal through
the Jak-STAT pathway of signaling molecules 40, 41 , and although the
signals for IL-4-induced proliferation are not thought to be
transmitted through this pathway 42 , there is at least the potential
for overlap of signal transduction between the two cytokines. We are
currently investigating interactions between intracellular signaling
pathways as a possible mechanism for the observed effect of IL-4 +
IL-12 on Th1. In any case, it appears that the proliferation-inducing
activity of IL-4 plus IL-12 on Th1 occurs through a direct effect. This
idea is supported by the fact that IL-4 and IL-12 had to be present
together to have a proliferative effect on Th1 (Fig. 3
).
IL-4 and IL-12 clearly play vastly different roles in Th cell differentiation, leading to the generation of Th2 and Th1, respectively. Therefore, it may initially seem counterintuitive that the two should have any kind of combined positive effects. For example, probably the most well-studied model in the Th1/Th2 paradigm is infection of mice with Leishmania major, in which mouse strains that develop an IL-12-driven Th1 response are disease resistant, and those that develop an IL-4-driven Th2 response succumb to the infection 43 . However, this type of immune response that is highly polarized in a single direction may be the exception rather than the rule. Successful control of infections may normally require a cooperative response comprised of both Th1 and Th2 components. Therefore, a more prototypical model may be the infection of mice with Plasmodium chabaudi chabaudi, in which a Th1 response is required for control of the initial stages of disease, and a Th2 response is required for final disease resolution 44, 45 . There are similar examples in humans, in which a combined Th1/Th2 response is necessary, such as infection with measles virus 46 . These situations demonstrate the potential benefit for cooperativity between Th1 and Th2, such as the positive effect of IL-2 on Th2 15 , and the effect of IL-4 + IL-12 on Th1 that we have investigated.
In conclusion, the proliferative effect of IL-4 and IL-12 on Th1
appears to represent a novel positive cross-regulatory effect of Th2
and APC. This stimulatory effect could increase numbers of potentially
relevant Th1 effector cells that have homed to an area of inflammation.
Such an area would logically contain a wide variety of cells and
cytokines, both inhibitory and stimulatory, including Th2 cells as an
IL-4 source, and activated macrophages or dendritic cells that could
provide IL-12 34, 35 . Whether or not the IL-4 + IL-12 effect actually
occurs, and the magnitude to which it occurs, would depend on the
dynamics of the balance between Th1 and Th2 in each case. Th1/Th2
cross-regulation has many inhibitory and stimulatory facets that
operate simultaneously during an immune response 8 . So, although
Th2-derived IL-10 can inhibit IL-12 production, its effect can be
counteracted by the IL-12-inducing effect of IFN-
derived from Th1.
Therefore, it is plausible to think that adequate concentrations of
IL-4 and IL-12 could be present to mediate the combined effect on Th1
during at least some immune responses.
Although Th1 clones that were seemingly resting responded to IL-4 + IL-12, they do probably represent chronically activated effector cells 47 , and spleen-derived Th effector cells also required prior activation to be able to respond to the two cytokines. We therefore favor the notion that IL-4 + IL-12 is a means to enhance or prolong an ongoing Th1 response, rather than a way to activate truly resting cells. This makes the scenario more plausible since it would probably be undesirable to promote indiscriminate proliferation of Th1 cells even if it was occurring within a confined area of inflammation. Naturally, many other positive and negative cross-regulatory pathways would also be operative at the same site 8 . Thus, the combined effect of IL-4 and IL-12 on Th1 appears to add an additional level of complexity to understanding or predicting the dynamics and eventual outcome of an immune response.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Penelope A. Morel, University of Pittsburgh Cancer Institute, W1057 Biomedical Science Tower, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213. ![]()
Received for publication March 25, 1998. Accepted for publication November 4, 1998.
| References |
|---|
|
|
|---|
involves interference with IL-1. J. Immunol. 158:3666.[Abstract]
ß T cell receptors. J. Immunol. 142:2736.[Abstract]
-producing CD4+ T cells following activation of naive CD4+ T cells. J. Immunol. 158:1085.[Abstract]
and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur. J. Immunol. 27:647.[Medline]
-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541.[Abstract]
production and activates IRAK and NF
B. Immunity 7:571.[Medline]
This article has been cited by other articles:
![]() |
J. Liu, B. E. Anderson, M. E. Robert, J. M. McNiff, S. G. Emerson, W. D. Shlomchik, and M. J. Shlomchik Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease Blood, December 1, 2001; 98(12): 3367 - 3375. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Weaver Jr., B. Liu, and R. Tisch Plasmid DNAs Encoding Insulin and Glutamic Acid Decarboxylase 65 Have Distinct Effects on the Progression of Autoimmune Diabetes in Nonobese Diabetic Mice J. Immunol., July 1, 2001; 167(1): 586 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Serreze, H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch Th1 to Th2 Cytokine Shifts in Nonobese Diabetic Mice: Sometimes an Outcome, Rather Than the Cause, of Diabetes Resistance Elicited by Immunostimulation J. Immunol., January 15, 2001; 166(2): 1352 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Klein, C. A. Newton, N. Nakachi, and H. Friedman {Delta}9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-{gamma}, IL-12, and IL-12 Receptor {beta}2 Responses to Legionella pneumophila Infection J. Immunol., June 15, 2000; 164(12): 6461 - 6466. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSC |